Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. - Trial NCT06374901
Access comprehensive clinical trial information for NCT06374901 through Pure Global AI's free database. This Phase 2 trial is sponsored by Xiangdong Cheng and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 134 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xiangdong Cheng
Zhejiang Cancer Hospital
Timeline & Enrollment
Phase 2
Apr 25, 2024
Mar 31, 2028
Primary Outcome
MRP (Main pathological response)
Summary
To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy
 in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced
 gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response
 rate (MPR).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06374901
Non-Device Trial